CSMCRI researcher awarded Haryana Vigyan Ratna 2022
Rajkot: Arvind Kumar, a scientist at the Central Salt & Marine Chemicals Research Institute (CSMCRI), has been conferred the Haryana Vigyan Ratna Award 2022 in recognition of his exceptional contributions to scientific research and innovation.
Tired of too many ads? go ad free now
The Haryana Vigyan Ratna Award, instituted by the govt of Haryana, is presented to eminent scientists who have made significant advancements in their respective fields. Each year, a maximum of two scientists are selected for the honour, which includes a cash prize of Rs 5 lakh.
In a statement, CSMCRI said, "Kumar's pioneering work in marine and chemical sciences has not only advanced scientific understanding but has also led to practical applications that benefit various industries and support environmental sustainability efforts."
Expressing his gratitude, Kumar remarked, "This award is a testament to the collective efforts of my colleagues and the scientific community. I am deeply humbled and motivated to continue pushing the boundaries of research for the betterment of society."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
T.N. Scientists Awards for 2022 and 2023 announced
The Tamil Nadu State Council for Science and Technology has announced the awardees of the Tamil Nadu Scientist Award for 2022 and 2023. The award is given to scientists from various disciplines including agriculture, biology, chemical sciences; environmental sciences; engineering and technology; mathematics; medicine; physics; social sciences and veterinary sciences. The award includes a cash prize of Rs. 50,000 and a citation. Heads of the research and educational institutions in the state nominate candidates for the awards. The council has constituted an advisory committee of experts for the award in each discipline. TNSCST member secretary S. Vincent said as many as 73 nominations were received for 2022. For the year 2023, the council received 96 nominations. The advisory committee has selected 12 scientists, one from each discipline.
News18
3 hours ago
- News18
IIT Delhi, AIIMS To Establish Centre Of Excellence For AI In Healthcare
Last Updated: The AI-CoE aims to develop AI-based solutions that support key national health programmes., IIT Delhi stated. IIT Delhi and AIIMS Delhi have entered into a Memorandum of Understanding (MoU) to create a Centre of Excellence for AI in Healthcare (AI-CoE). The MoU was signed by Prof. M. Srinivas, Director of AIIMS Delhi, and Prof. Rangan Banerjee, Director of IIT Delhi, during a ceremony at IIT Delhi. The AI-CoE aims to develop AI-based solutions that support key national health programmes. Last year, the Ministry of Education awarded the two institutes a grant of Rs 330 crore under the 'Make AI in India, Make AI Work for India' initiative, following a rigorous and competitive selection process. The proposed Centre of Excellence will serve as the implementation vehicle for this grant. 'This MoU marks the beginning of far-reaching collaborative research that has the potential to change the face of healthcare in the country," Prof. M. Srinivas, Director, AIIMS Delhi said. Prof. Rangan Banerjee, Director, IIT Delhi said, 'A partnership between AIIMS and IIT Delhi has the potential to transform Artificial Intelligence for affordable healthcare. We are delighted to be shaping this national center of excellence and hope that our output will impact the lives of Indians." Dr. Krithika Rangarajan, Chief Project Manager, who will lead the initiative from AIIMS Delhi, said, 'As we venture into this exciting new space, we look forward to guiding the marriage of healthcare with technology. We remain focused on keeping patients at the center of this effort and hope to build mechanisms that would benefit every citizen of the country." Prof. Chetan Arora, Chief Project Manager, who will lead the AI-CoE from IIT Delhi, said, 'We are excited to be part of this AI-CoE. The CoE will serve as a key research and resource center at the national and international level and aims to revolutionise the national public health system using indigenously developed AI systems and solutions. Our aim is to develop cuttingedge AI solutions to upscale health services, upskill our healthcare providers, and improve the accessibility of quality healthcare to remote and marginalised sections of our population."
Business Standard
6 hours ago
- Business Standard
SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials
Sun Pharma Advanced Research Company (SPARC) dropped 18.63% to Rs 159.15 after the company announced disappointing results from a key clinical trial. In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025.
